FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002860003> ?p ?o ?g. }

• W2002860003 endingPage "311" @default.
• W2002860003 startingPage "301" @default.
• W2002860003 abstract "The purpose of this study was to investigate the possible value of continuous administration of propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing chronic endoscopic sclerotherapy. Among 239 patients admitted for acute variceal bleeding, 85 with cirrhosis were randomized to receive sclerotherapy either alone (40) or in combination with propranolol (45). Sclerotherapy was carried out with an intravariceal injection of 5% ethanolamine oleate through a fiberoptic endoscope. The procedure was performed every week, until the esophageal varices at the gastroesophageal junction were too small for any further injections. Varices were reinjected if they recurred. Propranolol was given orally twice a day until heart rate was reduced by 25% in the resting position. The mean follow-up period was 23.2 and 24.2 months for sclerotherapy and the sclerotherapy plus propranolol groups, respectively. During this period a significant (P = 0.001) reduction in the recurrence of esophageal varices was observed in patients treated with the combination of sclerotherapy plus propranolol compared with those treated with sclerotherapy alone. However, the time of rebleeding from any source or from esophageal varices did not differ significantly between the two groups. In the sclerotherapy group 21 patients rebled (35 bleeding episodes) compared with 14 (22 episodes) in the combination therapy group. Patients in the sclerotherapy group were more prone to bleed from gastric varices and congestive gastropathy than patients treated with the combination of sclerotherapy plus propranolol (P = 0.012). Twenty-five patients in the endoscopic sclerotherapy group developed complications attributed to sclerotherapy compared with 23 patients in the sclerotherapy plus propranolol group. Complications directly attributable to propanolol were observed in 11 patients. Three of these patients stopped taking the drug due to heart failure (1) and flapping tremor (2). Eight patients (17.8%) died in the latter group while the corresponding figure in the sclerotherapy group was nine (22.5%). It is concluded that the continuous administration of propranolol may reduce incidences of recurrent upper gastrointestinal hemorrhage from gastric sources in patients with cirrhosis undergoing chronic sclerotherapy. The purpose of this study was to investigate the possible value of continuous administration of propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing chronic endoscopic sclerotherapy. Among 239 patients admitted for acute variceal bleeding, 85 with cirrhosis were randomized to receive sclerotherapy either alone (40) or in combination with propranolol (45). Sclerotherapy was carried out with an intravariceal injection of 5% ethanolamine oleate through a fiberoptic endoscope. The procedure was performed every week, until the esophageal varices at the gastroesophageal junction were too small for any further injections. Varices were reinjected if they recurred. Propranolol was given orally twice a day until heart rate was reduced by 25% in the resting position. The mean follow-up period was 23.2 and 24.2 months for sclerotherapy and the sclerotherapy plus propranolol groups, respectively. During this period a significant (P = 0.001) reduction in the recurrence of esophageal varices was observed in patients treated with the combination of sclerotherapy plus propranolol compared with those treated with sclerotherapy alone. However, the time of rebleeding from any source or from esophageal varices did not differ significantly between the two groups. In the sclerotherapy group 21 patients rebled (35 bleeding episodes) compared with 14 (22 episodes) in the combination therapy group. Patients in the sclerotherapy group were more prone to bleed from gastric varices and congestive gastropathy than patients treated with the combination of sclerotherapy plus propranolol (P = 0.012). Twenty-five patients in the endoscopic sclerotherapy group developed complications attributed to sclerotherapy compared with 23 patients in the sclerotherapy plus propranolol group. Complications directly attributable to propanolol were observed in 11 patients. Three of these patients stopped taking the drug due to heart failure (1) and flapping tremor (2). Eight patients (17.8%) died in the latter group while the corresponding figure in the sclerotherapy group was nine (22.5%). It is concluded that the continuous administration of propranolol may reduce incidences of recurrent upper gastrointestinal hemorrhage from gastric sources in patients with cirrhosis undergoing chronic sclerotherapy." @default.
• W2002860003 created "2016-06-24" @default.
• W2002860003 creator A5001310099 @default.
• W2002860003 creator A5002686004 @default.
• W2002860003 creator A5012483836 @default.
• W2002860003 creator A5024259728 @default.
• W2002860003 creator A5042468046 @default.
• W2002860003 creator A5059180467 @default.
• W2002860003 creator A5079475483 @default.
• W2002860003 date "1993-01-01" @default.
• W2002860003 modified "2023-09-26" @default.
• W2002860003 title "Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy. A randomized controlled trial" @default.
• W2002860003 cites W1493060657 @default.
• W2002860003 cites W1517026436 @default.
• W2002860003 cites W1522859716 @default.
• W2002860003 cites W1582378906 @default.
• W2002860003 cites W1607477581 @default.
• W2002860003 cites W1973798211 @default.
• W2002860003 cites W2007612534 @default.
• W2002860003 cites W2009371947 @default.
• W2002860003 cites W2014331949 @default.
• W2002860003 cites W2018234166 @default.
• W2002860003 cites W2025750036 @default.
• W2002860003 cites W2054125032 @default.
• W2002860003 cites W2056333581 @default.
• W2002860003 cites W2057022425 @default.
• W2002860003 cites W2065285468 @default.
• W2002860003 cites W2073443681 @default.
• W2002860003 cites W2078223580 @default.
• W2002860003 cites W2086413586 @default.
• W2002860003 cites W2095591944 @default.
• W2002860003 cites W2103194760 @default.
• W2002860003 cites W2128257517 @default.
• W2002860003 cites W2136558062 @default.
• W2002860003 cites W2137459480 @default.
• W2002860003 cites W2144089728 @default.
• W2002860003 cites W2148878677 @default.
• W2002860003 cites W2154593257 @default.
• W2002860003 cites W2167074458 @default.
• W2002860003 cites W2171941764 @default.
• W2002860003 cites W2408578678 @default.
• W2002860003 cites W3025344055 @default.
• W2002860003 cites W4293418190 @default.
• W2002860003 doi "https://doi.org/10.1016/s0168-8278(05)80586-0" @default.
• W2002860003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8301065" @default.
• W2002860003 hasPublicationYear "1993" @default.
• W2002860003 type Work @default.
• W2002860003 sameAs 2002860003 @default.
• W2002860003 citedByCount "50" @default.
• W2002860003 countsByYear W20028600032015 @default.
• W2002860003 countsByYear W20028600032017 @default.
• W2002860003 countsByYear W20028600032019 @default.
• W2002860003 countsByYear W20028600032020 @default.
• W2002860003 countsByYear W20028600032021 @default.
• W2002860003 crossrefType "journal-article" @default.
• W2002860003 hasAuthorship W2002860003A5001310099 @default.
• W2002860003 hasAuthorship W2002860003A5002686004 @default.
• W2002860003 hasAuthorship W2002860003A5012483836 @default.
• W2002860003 hasAuthorship W2002860003A5024259728 @default.
• W2002860003 hasAuthorship W2002860003A5042468046 @default.
• W2002860003 hasAuthorship W2002860003A5059180467 @default.
• W2002860003 hasAuthorship W2002860003A5079475483 @default.
• W2002860003 hasConcept C126322002 @default.
• W2002860003 hasConcept C141071460 @default.
• W2002860003 hasConcept C168563851 @default.
• W2002860003 hasConcept C2777214474 @default.
• W2002860003 hasConcept C2777595160 @default.
• W2002860003 hasConcept C2777819096 @default.
• W2002860003 hasConcept C2778012290 @default.
• W2002860003 hasConcept C2778151854 @default.
• W2002860003 hasConcept C2778230777 @default.
• W2002860003 hasConcept C2778808290 @default.
• W2002860003 hasConcept C2779195621 @default.
• W2002860003 hasConcept C71924100 @default.
• W2002860003 hasConcept C90924648 @default.
• W2002860003 hasConceptScore W2002860003C126322002 @default.
• W2002860003 hasConceptScore W2002860003C141071460 @default.
• W2002860003 hasConceptScore W2002860003C168563851 @default.
• W2002860003 hasConceptScore W2002860003C2777214474 @default.
• W2002860003 hasConceptScore W2002860003C2777595160 @default.
• W2002860003 hasConceptScore W2002860003C2777819096 @default.
• W2002860003 hasConceptScore W2002860003C2778012290 @default.
• W2002860003 hasConceptScore W2002860003C2778151854 @default.
• W2002860003 hasConceptScore W2002860003C2778230777 @default.
• W2002860003 hasConceptScore W2002860003C2778808290 @default.
• W2002860003 hasConceptScore W2002860003C2779195621 @default.
• W2002860003 hasConceptScore W2002860003C71924100 @default.
• W2002860003 hasConceptScore W2002860003C90924648 @default.
• W2002860003 hasIssue "2" @default.
• W2002860003 hasLocation W20028600031 @default.
• W2002860003 hasLocation W20028600032 @default.
• W2002860003 hasOpenAccess W2002860003 @default.
• W2002860003 hasPrimaryLocation W20028600031 @default.
• W2002860003 hasRelatedWork W151125730 @default.
• W2002860003 hasRelatedWork W1963531850 @default.
• W2002860003 hasRelatedWork W1993935922 @default.
• W2002860003 hasRelatedWork W1997565742 @default.
• W2002860003 hasRelatedWork W2045194958 @default.

• next